Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 15/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.42 |
| ▸ | SRC | P12931 | 4/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | YES1 | P07947 | 2/20 | 0.34 |
| ▸ | HCK | P08631 | 2/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | STK25 | O00506 | 1/20 | 0.34 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | GAK | O14976 | 1/20 | 0.34 |
| ▸ | MUSK | O15146 | 1/20 | 0.34 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038656 | 0.83 | AURKB (0.42) | IGF1RCCNE1CDK2AURKBSRC | |
| SCHEMBL3040342 | 0.81 | CCNE1 (0.43) | IGF1RCCNE2CCNE1CDK2AURKB | |
| SCHEMBL3044950 | 0.81 | AURKB (0.42) | IGF1RCCNE2CCNE1CDK2AURKB | |
| SCHEMBL3027778 | 0.80 | AURKB (0.42) | IGF1RCCNE2CCNE1CDK2AURKB | |
| SCHEMBL3035031 | 0.78 | SRC (0.51) | IGF1RCCNE2CCNE1CDK2AURKB | |
| SCHEMBL13221256 | 0.76 | AURKB (0.53) | IGF1RCCNE2CCNE1CDK2AURKB | |
| SCHEMBL3042680 | 0.76 | AURKB (0.55) | IGF1RAURKBSRCGSK3BAURKA | |
| SCHEMBL13221255 | 0.76 | AURKB (0.52) | IGF1RCCNE2CCNE1CDK2AURKB | |
| SCHEMBL13220983 | 0.76 | AURKB (0.46) | IGF1RCCNE2CCNE1CDK2AURKB | |
| SCHEMBL3037063 | 0.75 | AURKB (0.51) | IGF1RAURKBSRCGSK3BAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | claimed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | claimed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20060084650-A1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084650-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | IGF1R 787/4885CCNE2 1107/4885CCNE1 639/4885 |
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | IGF1R 787/4885CCNE2 1107/4885CCNE1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.